Please assess the completion status of the following clinical trial:

Trial Title: Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 years of age or older~* Patient meets colonoscopy requirements according to the American Gastroenterological Association~* Patient meets criteria for chronic constipation including weekly bowel movement frequency requirements and reports one or more symptoms of constipation according to protocol requirements~* Patient has successfully completed study requirements with no clinically-significant findings: physical exam, ECG, clinical laboratory tests~* Patient is fluent in English~Exclusion Criteria:~* Patient reports loose or watery stools~* Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain~* Patient may not take prohibited medications per protocol~* Medical diagnoses, medical conditions, or family history that would not make the patient a good candidate for the study or limit the patient's ability to complete the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 145 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 290 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 579 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- Matching Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).